Background: Thrombocytopenia is associated with increased mortality in the general population, but few data exist in patients with atrial fibrillation (AF) taking oral anticoagulants. We investigated factor determinants of thrombocytopenia in a large cohort of patients affected by AF and its association with total mortality. Methods and Results: Multicenter prospective cohort study, including 5215 patients with AF from the START (Survey on Anticoagulated Patients Register) registry, 3877 (74.3%) and 1338 (25.7%) on vitamin K or non–vitamin K antagonist oral anticoagulants, respectively. Thrombocytopenia was defined by a platelet count <150×109/L. Determinants of thrombocytopenia were investigated, and all-cause mortality was the primary survival end point of the study. Thrombocytopenia was present in 592 patients (11.4%). At multivariable logistic regression analysis, chronic kidney disease (odds ratio [OR], 1.257; P=0.030), active cancer (OR, 2.065; P=0.001), liver cirrhosis (OR, 7.635; P<0.001), and the use of diuretics (OR, 1.234; P=0.046) were positively associated with thrombocytopenia, whereas female sex (OR, 0.387; P<0.001) and the use of calcium channel blockers (OR, 0.787; P=0.032) were negatively associated. During a median follow-up of 19.2 months (9942 patient-years), 391 deaths occurred (rate, 3.93%/year). Mortality rate increased from 3.8%/year to 9.9%/year in patients with normal platelet count and in those with moderate-severe thrombocytopenia, respectively (log-rank test, P=0.009). The association between moderate-severe thrombocytopenia and mortality persisted after adjustment for CHA2DS2 VASc score (hazard ratio, 2.431; 95% CI, 1.254–4.713; P=0.009), but not in the fully adjusted multivariable Cox regression analysis model. Conclusions: Thrombocytopenia is common in patients with AF. Despite an increased incidence of mortality, thrombocytopenia was not associated with mortality at multivariable analysis. Thrombocytopenia may reflect the presence of comorbidities associated with poor survival in AF.

Thrombocytopenia and mortality risk in patients with atrial fibrillation. an analysis from the START registry / Pastori, D.; Antonucci, E.; Violi, F.; Palareti, G.; Pignatelli, P.; Testa, S.; Paoletti, O.; Cosmi, B.; Guazzaloca, G.; Migliaccio, L.; Poli, D.; Marcucci, R.; Maggini, N.; Pengo, V.; Falanga, A.; Lerede, T.; Ruocco, L.; Martini, G.; Pedrini, Simona; Bertola, F.; Masciocco, L.; Saracino, P.; Benvenuto, A.; Vasselli, C.; Violi, F.; Pignatelli, P.; Pastori, D.; Grandone, E.; Colaizzo, D.; Marzolo, M.; Pinelli, M.; Ageno, W.; Colombo, G.; Bucherini, E.; Serra, D.; Toma, A.; Barbera, P.; Paparo, C.; Insana, A.; Rupoli, S.; Malcangi, G.; Zighetti, M. L.; Mangione, C.; Lione, D.; Casasco, P.; Nante, G.; Tosetto, A.; Oriana, V.; Liberato, N. L.. - In: JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE. - ISSN 2047-9980. - 8:21(2019). [10.1161/JAHA.119.012596]

Thrombocytopenia and mortality risk in patients with atrial fibrillation. an analysis from the START registry

Pastori D.;Violi F.
;
Pignatelli P.;
2019

Abstract

Background: Thrombocytopenia is associated with increased mortality in the general population, but few data exist in patients with atrial fibrillation (AF) taking oral anticoagulants. We investigated factor determinants of thrombocytopenia in a large cohort of patients affected by AF and its association with total mortality. Methods and Results: Multicenter prospective cohort study, including 5215 patients with AF from the START (Survey on Anticoagulated Patients Register) registry, 3877 (74.3%) and 1338 (25.7%) on vitamin K or non–vitamin K antagonist oral anticoagulants, respectively. Thrombocytopenia was defined by a platelet count <150×109/L. Determinants of thrombocytopenia were investigated, and all-cause mortality was the primary survival end point of the study. Thrombocytopenia was present in 592 patients (11.4%). At multivariable logistic regression analysis, chronic kidney disease (odds ratio [OR], 1.257; P=0.030), active cancer (OR, 2.065; P=0.001), liver cirrhosis (OR, 7.635; P<0.001), and the use of diuretics (OR, 1.234; P=0.046) were positively associated with thrombocytopenia, whereas female sex (OR, 0.387; P<0.001) and the use of calcium channel blockers (OR, 0.787; P=0.032) were negatively associated. During a median follow-up of 19.2 months (9942 patient-years), 391 deaths occurred (rate, 3.93%/year). Mortality rate increased from 3.8%/year to 9.9%/year in patients with normal platelet count and in those with moderate-severe thrombocytopenia, respectively (log-rank test, P=0.009). The association between moderate-severe thrombocytopenia and mortality persisted after adjustment for CHA2DS2 VASc score (hazard ratio, 2.431; 95% CI, 1.254–4.713; P=0.009), but not in the fully adjusted multivariable Cox regression analysis model. Conclusions: Thrombocytopenia is common in patients with AF. Despite an increased incidence of mortality, thrombocytopenia was not associated with mortality at multivariable analysis. Thrombocytopenia may reflect the presence of comorbidities associated with poor survival in AF.
2019
atrial fibrillation; mortality; thrombocytopenia
01 Pubblicazione su rivista::01a Articolo in rivista
Thrombocytopenia and mortality risk in patients with atrial fibrillation. an analysis from the START registry / Pastori, D.; Antonucci, E.; Violi, F.; Palareti, G.; Pignatelli, P.; Testa, S.; Paoletti, O.; Cosmi, B.; Guazzaloca, G.; Migliaccio, L.; Poli, D.; Marcucci, R.; Maggini, N.; Pengo, V.; Falanga, A.; Lerede, T.; Ruocco, L.; Martini, G.; Pedrini, Simona; Bertola, F.; Masciocco, L.; Saracino, P.; Benvenuto, A.; Vasselli, C.; Violi, F.; Pignatelli, P.; Pastori, D.; Grandone, E.; Colaizzo, D.; Marzolo, M.; Pinelli, M.; Ageno, W.; Colombo, G.; Bucherini, E.; Serra, D.; Toma, A.; Barbera, P.; Paparo, C.; Insana, A.; Rupoli, S.; Malcangi, G.; Zighetti, M. L.; Mangione, C.; Lione, D.; Casasco, P.; Nante, G.; Tosetto, A.; Oriana, V.; Liberato, N. L.. - In: JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE. - ISSN 2047-9980. - 8:21(2019). [10.1161/JAHA.119.012596]
File allegati a questo prodotto
File Dimensione Formato  
Pastori_Thrombocytopenia_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 327.29 kB
Formato Adobe PDF
327.29 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1386270
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 17
social impact